Phase IIb Apremilast Study Shows Positive Data in Psoriasis Patients

Pharmaceutical company Celgene Corp. said Tuesday that clinical data from an investigational Phase IIb study of apremilast in patients with moderate-to-severe plaque-type psoriasis revealed Psoriasis Area and Severity Index or PASI 75 of 41% for apremilast 30 mg twice daily, compared to 6% for placebo at 16 weeks.
RTTNews